Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)

May 6, 2026 12:49 AM

Stifel analyst Annabel Samimy reiterated a Buy rating and $18.00 price target on Trevi Therapeutics (NASDAQ: TRVI)The analyst comments: “We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found